Veradigm (MDRX) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 06, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		180,680,911

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 104,301	$ 95,607
Restricted cash	5,123	1,003
Accounts receivable, net of allowance of $36,030 and $32,670 as of September 30, 2017 and December 31, 2016, respectively	442,872	405,172
Prepaid expenses and other current assets	115,701	102,551
Total current assets	667,997	604,333
Available for sale marketable securities	0	149,100
Fixed assets, net	165,434	148,810
Software development costs, net	207,055	163,879
Intangible assets, net	717,233	741,403
Goodwill	1,971,950	1,924,052
Deferred taxes, net	4,234	2,791
Other assets	149,485	97,791
Total assets	3,883,388	3,832,159
Current liabilities:
Accounts payable	114,291	126,144
Accrued expenses	71,820	86,135
Accrued compensation and benefits	70,037	64,291
Deferred revenue	392,462	363,772
Current maturities of long-term debt	24,550	15,158
Current maturities of non-recourse long-term debt - Netsmart	2,749	2,451
Current maturities of capital lease obligations	8,517	9,126
Total current liabilities	684,426	667,077
Long-term debt	747,441	717,853
Non-recourse long-term debt - Netsmart	625,513	576,918
Long-term capital lease obligations	7,708	9,877
Deferred revenue	19,319	18,009
Deferred taxes, net	145,432	141,752
Other liabilities	86,474	39,787
Total liabilities	2,316,313	2,171,273
Redeemable convertible non-controlling interest - Netsmart	420,572	387,685
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2017 and December 31, 2016	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2017 and December 31, 2016; 269,154 and 180,650 shares issued and outstanding as of September 30, 2017, respectively; 267,997 and 180,510 shares issued and outstanding as of December 31, 2016, respectively	2,692	2,680
Treasury stock: at cost, 88,504 and 87,487 shares as of September 30, 2017 and December 31, 2016, respectively	(322,735)	(310,993)
Additional paid-in capital	1,782,432	1,789,959
Accumulated deficit	(354,928)	(187,351)
Accumulated other comprehensive loss	(2,067)	(61,829)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,105,394	1,232,466
Non-controlling interest	41,109	40,735
Total stockholders’ equity	1,146,503	1,273,201
Total liabilities and stockholders’ equity	$ 3,883,388	$ 3,832,159

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 36,030	$ 32,670
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	269,154,000	267,997,000
Common stock, shares outstanding	180,650,000	180,510,000
Treasury stock at cost, shares	88,504,000	87,487,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Software delivery, support and maintenance	$ 294,221	$ 252,692	$ 845,951	$ 731,721
Client services	155,221	139,692	443,057	392,742
Total revenue	449,442	392,384	1,289,008	1,124,463
Cost of revenue:
Software delivery, support and maintenance	86,893	86,537	259,361	240,860
Client services	132,629	116,415	379,797	335,957
Amortization of software development and acquisition-related assets	28,001	23,273	81,788	62,905
Total cost of revenue	247,523	226,225	720,946	639,722
Gross profit	201,919	166,159	568,062	484,741
Selling, general and administrative expenses	117,352	98,778	340,234	277,733
Research and development	51,057	45,142	146,748	140,070
Asset impairment charges	0	0	0	4,650
Amortization of intangible and acquisition-related assets	8,137	5,365	23,340	14,944
Income from operations	25,373	16,874	57,740	47,344
Interest expense	(22,252)	(19,367)	(62,722)	(42,757)
Other (loss) income, net	(570)	(6)	(545)	466
Impairment of and losses on long-term investments	(20,700)	0	(165,290)	0
Equity in net income (loss) of unconsolidated investments	449	0	706	(7,501)
(Loss) income before income taxes	(17,700)	(2,499)	(170,111)	(2,448)
Income tax benefit (provision)	238	2,656	1,073	2,596
Net (loss) income	(17,462)	157	(169,038)	148
Less: Net income attributable to non-controlling interests	(163)	(151)	(352)	(142)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	(10,191)	(32,887)	(18,344)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (28,587)	$ (10,185)	$ (202,277)	$ (18,338)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.16)	$ (0.06)	$ (1.12)	$ (0.10)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.16)	$ (0.06)	$ (1.12)	$ (0.10)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (17,462)	$ 157	$ (169,038)	$ 148
Other comprehensive income (loss):
Foreign currency translation adjustments	693	150	3,040	(49)
Change in unrealized gain (loss) on available for sale securities	(4)	9,750	56,507	(8,365)
Change in fair value of derivatives qualifying as cash flow hedges	(692)	686	341	900
Other comprehensive (loss) income before income tax benefit (expense)	(3)	10,586	59,888	(7,514)
Income tax benefit (expense) related to items in other comprehensive loss	271	(270)	(126)	(355)
Total other comprehensive income (loss)	268	10,316	59,762	(7,869)
Comprehensive loss	(17,194)	10,473	(109,276)	(7,721)
Less: Comprehensive income attributable to non-controlling interests	(163)	(151)	(352)	(142)
Comprehensive (loss) income, net	$ (17,357)	$ 10,322	$ (109,628)	$ (7,863)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net (loss) income	$ (169,038)	$ 148
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	155,108	120,473
Stock-based compensation expense	28,140	29,717
Excess tax benefits from stock-based compensation	0	(972)
Deferred taxes	(5,324)	(4,198)
Asset impairment charges	0	4,650
Impairment of and losses on long-term investments	165,290	0
Equity in net (income) loss of unconsolidated investments	(706)	7,501
Other losses, net	3,711	2,057
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(31,256)	(12,723)
Prepaid expenses and other assets	(6,939)	3,381
Accounts payable	2,908	26,341
Accrued expenses	(6,196)	(8,843)
Accrued compensation and benefits	5,930	(12,933)
Deferred revenue	18,661	30,587
Other liabilities	12,894	(28)
Net cash provided by operating activities	173,183	185,158
Cash flows from investing activities:
Capital expenditures	(40,216)	(25,046)
Capitalized software	(107,079)	(69,994)
Cash paid for business acquisitions, net of cash acquired	(54,308)	(935,280)
Purchases of equity securities, other investments and related intangible assets	(5,423)	(20,685)
Other proceeds from investing activities	215	37
Net cash used in investing activities	(206,811)	(1,050,968)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	0	84
Proceeds from issuance of redeemable convertible preferred stock - Netsmart	0	333,606
Excess tax benefits from stock-based compensation	0	972
Taxes paid related to net share settlement of equity awards	(6,777)	(7,379)
Payments of capital lease obligations	(9,013)	(3,858)
Credit facility payments	(115,281)	(80,507)
Credit facility borrowings, net of issuance costs	189,698	654,135
Repurchase of common stock	(12,077)	(71,082)
Payment of acquisition financing obligations	(2,398)	0
Proceeds from sales of subsidiary shares to non-controlling interest	1,494	0
Net cash provided by financing activities	45,646	825,971
Effect of exchange rate changes on cash and cash equivalents	796	217
Net increase (decrease) in cash and cash equivalents	12,814	(39,622)
Cash, cash equivalents and restricted cash, beginning of period	96,610	116,873
Cash, cash equivalents and restricted cash, end of period	$ 109,424	$ 77,251

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2017 and 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have decided to adopt the standard effective January 1, 2018 using the modified retrospective method. We have completed our assessment of our systems, available data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Through evaluation of the standard’s requirements, the Company plans to utilize several practical expedients including (i) viewing shipping and handling as a fulfillment cost versus a distinct performance obligation, and (ii) the right to invoice expedient as it relates to transaction-related revenue activities. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware sales, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscription contracts that include both software licenses and software support and maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue license recognition treatment required under the new standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. Additionally, we currently only capitalize direct sales commissions that are specifically associated with new or renewal contracts. The new revenue recognition guidance requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. As part of our implementation efforts, we have identified certain indirect commissions and other payments that would be eligible for capitalization under the new guidance because they are also incremental costs solely associated with new or renewal contracts that we expect to recover. As result, we expect to record a deferral for such costs, which could be significant, upon adoption of the new guidance on January 1, 2018. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Business Combinations	2. Business Combinations 2017 Business Combinations Acquisition of DeVero On July 17, 2017, Netsmart (as defined below) completed the acquisition of DeVero, Inc. (“DeVero”), a healthcare technology company that develops electronic medical record solutions for home healthcare and hospice, for an aggregate purchase price of $50.7 million in cash. The purchase price was funded through incremental borrowings under Netsmart’s debt facilities. The allocation of the aggregate consideration is as follows: $32.9 million of goodwill; $19.0 million of intangible assets related to customer relationships; $6.9 million of intangible assets related to technology; $2.0 million of cash; other assets of $1.5 million; accounts payable and accrued expenses of $2.3 million; deferred revenue of $0.9 million; and deferred income taxes of $8.4 million. This allocation is preliminary and subject to changes, which could be significant, as liabilities related to deferred taxes are finalized, and additional information becomes available. The acquired intangible assets related to technology and customer relationships will be amortized over their estimated useful lives of 7-20 years using a method that approximates the pattern of economic benefits to be gained by the intangible assets. The goodwill is not deductible for tax purposes. The results of operations of DeVero were not material to our consolidated results of operations for the three and nine months ended September 30, 2017 . NantHealth Asset Purchase Agreement On August 25, 2017, the Company completed the acquisition of substantially all of the assets relating to the provider/patient engagement solutions business of NantHealth, Inc. (“NantHealth”). The consideration for the transaction included the 15,000,000 shares of common stock of NantHealth that had been held by the Company as available for sale securities and which had a fair value of $42.8 million at the time of the transaction. The transaction also includes adjustments for working capital and deferred revenue obligations, as well as a modification of the commercial agreement between the parties. Total consideration for the transaction was as follows: (In thousands) Cash $ 1,742 NantHealth common stock 42,750 Less: Value assigned to modification of existing commercial agreement with NantHealth (22,700 ) Total consideration for NantHealth provider/patient solutions business $ 21,792 The allocation of the fair value of the consideration transferred as of the acquisition date of August 25, 2017 is shown in the table below. (In thousands) Cash and cash equivalents $ 21 Accounts receivable, net 2,078 Prepaid expenses and other current assets 1,806 Fixed assets 7,099 Intangible assets 12,400 Goodwill 9,058 Other assets 205 Accounts payable and accrued expenses (1,575 ) Deferred revenue (9,300 ) Net assets acquired $ 21,792 The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 19 $ 9,200 Technology 5 3,000 Tradenames 5 200 $ 12,400 Asset Purchase Agreement with Third Party On March 31, 2017, Netsmart entered into an Asset Purchase Agreement with a third party, for an aggregate cash consideration of $4.0 million, to acquire intellectual property, certain contractual relationships and certain associates. This transaction has been accounted for as a business combination. The Asset Purchase Agreement provides for contingent consideration to be paid to the third party based on the number of customers of the third party that migrate to Netsmart’s electronic health record product. The value of the contingent consideration has been estimated to be $0.7 million. Netsmart accrued $0.5 million at September 30, 2017 within other liabilities. This amount represents the discounted fair value of the contingent consideration. This transaction resulted in the recognition of goodwill of $4.4 million. . 2016 Business Combinations Update Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”), to form a joint business entity to which we contributed our Homecare TM TM As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare TM business within Netsmart over the next five years, at which time the restriction on any unused funds will lapse. As of September 30, 2017, there is $11.3 million remaining in the escrow account. Acquisition of HealthMEDX On October 27, 2016, Netsmart completed the acquisition of HealthMEDX, LLC, a Delaware limited liability company (“HealthMEDX”), for an aggregate consideration of $39.2 million. HealthMEDX is a provider of electronic medical record solutions for long-term and post-acute care including continuing care retirement communities, assisted living, independent living, skilled nursing and home care providers. During the three months ended March 31, 2017, we finalized the allocation of the fair value of the consideration transferred and recorded a measurement period adjustment of $0.1 million related to the fair value of liabilities with an offset to goodwill. Other Acquisitions During the second quarter of 2017 we recorded final measurement period adjustments against goodwill related to the Company’s acquisitions of third parties during the fourth quarter of 2016. Supplemental Information The supplemental pro forma results below for the three and nine months ended September 30, 2017 and 2016 were calculated after applying our accounting policies and adjusting the results of NantHealth’s provider /patient engagement solutions business to reflect (i) the additional amortization of acquired intangible assets and (ii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value, that would have been recognized assuming the acquisition occurred on January 1, 2016, together with the consequential tax effects. The supplemental pro forma results were also adjusted to exclude acquisition-related and transaction costs incurred during the 2017 period. The revenue and net loss of NantHealth’s provider/patient solutions business since August 25, 2017 are included in our consolidated statement of operations for the three and nine months ended September 30, 2017. The supplemental pro forma results below for the three and nine months ended September 30, 2016 were calculated after applying our accounting policies and adjusting the results of Netsmart and HealthMEDX to reflect (i) the additional depreciation and amortization that would have resulted from the fair value adjustments to property, plant and equipment and intangible assets, (ii) the additional interest expense associated with Netsmart’s borrowings under new term loans and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value, that would have been recognized assuming both acquisitions occurred on January 1, 2015, together with the consequential tax effects. The supplemental pro forma results were also adjusted to exclude acquisition-related and transaction costs incurred during the 2016 period. The effects of transactions between Allscripts and Netsmart during the periods presented have been eliminated in the supplemental pro forma data. The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three and nine months ended September 30, 2016. The below supplemental pro forma data for the combined entity is presented under the assumption that the Netsmart and HealthMEDX acquisitions occurred on January 1, 2015 and the NantHealth provider/patient solutions business acquisition occurred on January 1, 2016. The three and nine months ended September 30, 2017 only reflect pro forma adjustments related to the NantHealth provider/patient solutions business, as Netsmart and HealthMEDX are included for the full 2017 periods. (In thousands, except per share amounts) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 52,621 $ 96,855 Net loss $ (11,126 ) $ (18,239 ) Actual from NantHealth since acquisition date of August 25, 2017: Revenue $ 648 $ 0 $ 648 $ 0 Net loss $ (628 ) $ 0 $ (628 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 451,142 $ 1,296,008 $ 403,741 $ 1,229,471 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (27,260 ) $ (223,449 ) $ (14,799 ) $ (66,220 ) Loss per share, basic and diluted $ (0.15 ) $ (1.24 ) $ (0.08 ) $ (0.35 )

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	3. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 financial instruments included our investment in NantHealth common stock. Refer to Note 11, “Other Comprehensive Income,” Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The sensitivity of changes in the unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 0 $ 0 $ 0 $ 0 $ 149,100 $ 0 $ 0 $ 149,100 1.25% Call Option Other assets 0 0 44,882 44,882 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (45,973 ) (45,973 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 1,362 0 1,362 0 1,021 0 1,021 Total $ 0 $ 1,362 $ (1,091 ) $ 271 $ 149,100 $ 1,021 $ (579 ) $ 149,542 Long-term Investments The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at September 30, 2017 Investment September 30, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 4,142 $ 2,436 Cost method investments 7 32,784 26,572 26,041 Total equity investments 10 $ 34,442 $ 30,714 $ 28,477 _________________________________ (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of September 30, 2017, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Impairment of Long- term Investments Each quarter, management performs an assessment of each of our investments on an individual basis to determine if any declines in fair value are other than temporary. Based on management's assessment , the Company determined that the decline in fair value of our available for sale marketable securities was other than temporary based on a number of factors, including, but not limited to, uncertainty regarding our intent to hold these investments for a period of time that would be sufficient to recover our cost basis in the event of a market recovery, the fact that the fair value of each investment had continued to decline below cost over the period held, and the Company's uncertainty around the near-term prospects for certain of the investments. The cost basis of these marketable securities prior to recognizing the impairment charges was approximately $205.6 million. The Company determined the fair value of these securities based on Level 1 inputs. The aggregate carrying value of this equity investment prior to recognizing the impairment charge was $2.1 million. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as September 30, 2017, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and nine months ended September 30, 2017 and 2016 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the three and nine months periods ended September 30, 2017 and 2016 include stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2017 and 2016. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 378 $ 979 $ 2,491 $ 3,209 Client services 899 884 3,464 3,512 Total cost of revenue 1,277 1,863 5,955 6,721 Selling, general and administrative expenses 7,193 6,464 17,793 17,972 Research and development 1,934 1,446 6,643 6,141 Total stock-based compensation expense $ 10,404 $ 9,773 $ 30,391 $ 30,834 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and nine months ended September 30, 2017 and 2016. We granted stock-based awards as follows: Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 11 $ 13.73 1,908 $ 12.38 Performance-based restricted stock units with a service condition 38 $ 13.25 610 $ 12.01 Market-based restricted stock units with a service condition 0 $ 0.00 613 $ 13.34 49 $ 13.36 3,131 $ 12.50 During the nine months ended September 30, 2017 and the year ended December 31, 2016, 1.2 million and 1.5 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the nine months ended September 30, 2017 and year ended December 31, 2016 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2017 and 2016 were 569 thousand and 572 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On November 17, 2016, we announced that our Board approved a stock purchase program under which we may repurchase up to $200 million of our common stock through December 31, 2019. During the three and nine months ended September 30, 2017, we repurchased 0.0 million and 1.0 million shares, respectively, of our common stock under the program for a total of $12.1 million. The approximate dollar value of shares that may yet be purchased under the program as of September 30, 2017 was $163.9 million. Netsmart Stock-based Compensation Expense Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 42 $ 31 $ 17 $ 56 Client services 56 33 (12 ) 70 Total cost of revenue 98 64 5 126 Selling, general and administrative expenses 2,302 1,617 (557 ) 2,945 Research and development 63 43 (13 ) 79 Total stock-based compensation expense (benefit) $ 2,463 $ 1,724 $ (565 ) $ 3,150 At September 30, 2017, the liability for outstanding awards was $5.2 During the three and nine months ended September 30, 2017, 3.3 million option unit awards were granted by Netsmart . Of the 3.3 million unit awards granted, 2.1 million were time-based and 1.2 million were performance-based. These options were issued at an exercise price of $1.00.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2017 2016 2017 2016 Basic Loss per Common Share: Net (loss) income $ (17,462 ) $ 157 $ (169,038 ) $ 148 Less: Net income attributable to non-controlling interests (163 ) (151 ) (352 ) (142 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,962 ) (10,191 ) (32,887 ) (18,344 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (28,587 ) $ (10,185 ) $ (202,277 ) $ (18,338 ) Weighted-average common shares outstanding 180,634 186,226 180,864 187,190 Basic Loss per Common Share $ (0.16 ) $ (0.06 ) $ (1.12 ) $ (0.10 ) Diluted Loss per Common Share: Net (loss) income $ (17,462 ) $ 157 $ (169,038 ) $ 148 Less: Net income attributable to non-controlling interests (163 ) (151 ) (352 ) (142 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,962 ) (10,191 ) (32,887 ) (18,344 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (28,587 ) $ (10,185 ) $ (202,277 ) $ (18,338 ) Weighted-average common shares outstanding 180,634 186,226 180,864 187,190 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 180,634 186,226 180,864 187,190 Diluted Loss per Common Share $ (0.16 ) $ (0.06 ) $ (1.12 ) $ (0.10 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three and nine months ended September 30, 2017 and 2016, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,085 27,580 26,636 26,219

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: September 30, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 638,118 $ (388,913 ) $ 249,205 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 843,458 (454,430 ) 389,028 813,021 (430,960 ) 382,061 Total $ 1,481,576 $ (843,343 ) $ 638,233 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,971,950 1,924,052 Total $ 2,050,950 $ 2,003,052 Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 DeVero acquisition 0 0 32,943 32,943 Nanthealth provider/patient solutions business 0 9,058 0 9,058 Other additions 405 47 4,503 4,955 Foreign exchange translation 942 0 0 942 Balance as of September 30, 2017 $ 845,184 $ 413,980 $ 712,786 $ 1,971,950 There were no accumulated impairment losses associated with our goodwill as of September 30, 2017 or December 31, 2016. Additions during the third quarter of 2017 include goodwill of $9.1 million arising from Allscripts’ purchase of NantHealth’s provider/patient engagement solutions business and $32.9 million arising from Netsmart’s acquisition of DeVero. Other additions during the nine months ended September 30, 2017 include additions arising from Netsmart’s Asset Purchase Agreement with a third party and measurement period adjustments against goodwill related to the Company’s acquisitions of third parties in late 2016. Refer to Note 2, “Business Combinations,” for additional information regarding these transactions.

Asset and Long-term Investment

Asset and Long-term Investment Impairment Charges	9 Months Ended
	Sep. 30, 2017
Asset And Long Term Investment Impairment Charges [Abstract]
Asset and Long-term Investment Impairment Charges	7. Asset and Long-term Investment Impairment Charges We incurred the following asset and long-term investment impairment charges: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Asset impairment charges $ 0 $ 0 $ 0 $ 4,650 Impairment of and losses on long-term investments $ 20,700 $ 0 $ 165,290 $ 0 During the first quarter of 2016, we incurred non-cash asset impairment charges which included $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. During the nine months ended September 30, 2017, we recognized non-cash charges of $165.3 million including other than temporary impairment charges of $144.6 million during the second quarter of 2017 associated with two of the Company’s long-term investments based on management’s assessment of the likelihood of near-term recovery of the investments’ value. The majority of the impairment charges relate to our investment in NantHealth common stock. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 11, “Other Comprehensive Income,” for further information regarding these impairments. During the three months ended September 30, 2017, we realized an additional $20.7 million loss upon the final disposition of the NantHealth common stock. Refer to Note 2, “Business Combinations,” for information regarding the divestiture of our investment in NantHealth common stock in connection with our acquisition of certain assets related to NantHealth’s provider/patient engagement solutions business.

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consists of the following: September 30, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 39,319 $ 305,681 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 470,000 3,690 466,310 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 480,533 11,482 469,051 432,925 11,655 421,270 Second Lien Term Loan 167,000 7,789 159,211 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,462,533 $ 62,280 $ 1,400,253 $ 1,386,813 $ 74,433 $ 1,312,380 Less: Debt payable within one year - excluding Netsmart 25,000 450 24,550 15,638 480 15,158 Less: Debt payable within one year - Netsmart 4,866 2,117 2,749 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,432,667 $ 59,713 $ 1,372,954 $ 1,366,824 $ 72,053 $ 1,294,771 Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Interest expense $ 5,577 $ 3,896 $ 15,079 $ 11,029 Amortization of discounts and debt issuance costs 3,674 3,522 10,867 10,401 Netsmart: Interest expense (1) 12,107 11,019 34,188 19,549 Amortization of discounts and debt issuance costs 894 930 2,588 1,778 Total interest expense $ 22,252 $ 19,367 $ 62,722 $ 42,757 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 3,234 $ 3,234 Amortization of discounts and debt issuance costs 3,342 3,185 9,866 9,401 Total interest expense related to the 1.25% Notes $ 4,420 $ 4,263 $ 13,100 $ 12,635 Allscripts Senior Secured Credit Facility As of September 30, 2017, $225.0 million under a term loan, $245.0 million under our revolving credit facility, and $0.8 million in letters of credit were outstanding under our senior secured credit facility. As of September 30, 2017, the interest rate on the borrowings under our senior secured credit facility was LIBOR plus 2.25%, which totaled 3.49%. We were in compliance with all covenants under the senior secured credit facility agreement as of September 30, 2017. As of September 30, 2017, we had $304.2 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. Refer to Note 15, “Subsequent Events,” for information regarding an additional borrowing of $185.0 million under our revolving credit facility to fund a business acquisition that occurred subsequent to September 30, 2017. As of September 30, 2017, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. Netsmart Non-Recourse Debt As of September 30, 2017, $480.5 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and no amounts under the Netsmart Revolving Facility (collectively, the “Credit Agreements”) were outstanding. As of September 30, 2017, the interest rate on the borrowings under the Netsmart First Lien Term Loan was Adjusted LIBO plus 4.50%, which totaled 5.83%, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.50%, which totaled 10.82%, and the interest rate on the borrowings under the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 6.08%. Netsmart was in compliance with all covenants under its Credit Agreements as of September 30, 2017. As of September 30, 2017, Netsmart had $50.0 million available, with no outstanding letters of credit commitments, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes future debt payment obligations as of September 30, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 225,000 6,250 28,125 40,625 150,000 0 0 Revolving Facility (2) 245,000 0 0 0 245,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 480,533 1,217 4,866 4,866 4,866 4,866 459,852 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,462,533 $ 7,467 $ 32,991 $ 45,491 $ 744,866 $ 4,866 $ 626,852 (1) (2)

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 (Loss) income before income taxes $ (17,700 ) $ (2,499 ) $ (170,111 ) $ (2,448 ) Income tax benefit (provision) $ 238 $ 2,656 $ 1,073 $ 2,596 Effective tax rate 1.3 % 106.3 % 0.6 % 106.0 % Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three and nine months ended September 30, 2017, compared with the prior year comparable periods, differs primarily due to $64.2 million of valuation allowance in the nine months ended September 30, 2017 for deferred taxes on a capital loss carryforward, which can only can be deductible to the extent of offsetting capital gains. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). We recorded $67.8 million of valuation allowance during the nine months ended September 30, 2017 related to deferred tax assets associated with net operating loss carryforwards, credit carryforwards and other deferred tax assets not expected to be realized. Effective January 1, 2017, we adopted ASU 2016-09. The guidance in ASU 2016-09, among other things, will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled as a discrete item in the period in which they occur. In the nine months ended September 30, 2017, we recorded $1.5 million of tax expense for awards in which the compensation cost recorded was higher than the tax deductions for the awards. We recorded an offsetting release of valuation allowance in the quarter of $1.5 million, the effect of which has already been included in the valuation allowance amount recorded in the nine months ended September 30, 2017 noted above. ASU 2016-09 requires entities to recognize excess tax benefits, regardless of whether the tax deduction reduces taxes payable. As part of adopting the new standard, we recorded a gross cumulative effect adjustment of $5.6 million to the opening balance of accumulated deficit to create a deferred tax asset to recognize excess tax benefits not previously recorded. The net decrease to accumulated deficit was $1.8 million due to the recognition of a corresponding valuation allowance of $3.8 million. Our unrecognized income tax benefits were $12.0 million and $11.4 million as of September 30, 2017 and December 31, 2016, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,362 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 44,882 N/A 1.25% Embedded cash conversion option N/A Other liabilities 45,973 Total derivatives $ 46,244 $ 45,973 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of September 30, 2017, there were 9 forward contracts outstanding that were staggered to mature monthly starting in October 2017 and ending in June 2018. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond June 2018. As of September 30, 2017, the notional amount of each outstanding forward contract was 120 million INR, or the equivalent of $1.8 million, based on the exchange rate between the United States dollar and the INR in effect as of September 30, 2017. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three and nine months ended September 30, 2017, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of September 30, 2017, we estimate that $1.4 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Foreign exchange contracts $ 16 $ 2,323 Cost of Revenue $ 241 $ 674 Selling, general and administrative expenses 184 515 Research and development $ 283 $ 793 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Foreign exchange contracts $ 971 $ 1,172 Cost of Revenue $ 88 $ 84 Selling, general and administrative expenses 71 68 Research and development $ 126 $ 120 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 1.25% Call Option $ 12,837 $ 2,306 $ 27,802 $ (39,404 ) 1.25% Embedded cash conversion option (13,043 ) (2,362 ) (28,314 ) 39,609 Net (loss) gain included in other income, net $ (206 ) $ (56 ) $ (512 ) $ 205

Other Comprehensive Income

Other Comprehensive Income	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net (Losses) Gains on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (1) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive income (loss) before reclassifications 3,040 (106,355 ) 1,421 (101,894 ) Net losses (gains) reclassified from accumulated other comprehensive loss (2) 0 162,865 (1,209 ) 161,656 Net other comprehensive income 3,040 56,510 212 59,762 Balance as of September 30, 2017 (3) $ (2,988 ) $ 90 $ 831 $ (2,067 ) ______________________________________________________ (1) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. (2) Reclassification adjustment related to other-than-temporary impairment and loss on disposition of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our disposition of the NantHealth common stock. (3) Net of taxes of $531 thousand for unrealized net gains on foreign exchange contract derivatives and $58 thousand for unrealized net gains on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (49 ) (8,365 ) 710 (7,704 ) Net losses reclassified from accumulated other comprehensive loss 0 0 (165 ) (165 ) Net other comprehensive (loss) income (49 ) (8,365 ) 545 (7,869 ) Balance as of September 30, 2016 (2) $ (4,549 ) $ (8,365 ) $ 803 $ (12,111 ) ____________________________________________________________________________ (1) (2) Net of taxes of $ Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 693 $ 0 $ 693 $ 150 $ 0 $ 150 Available for sale securities: Net loss arising during the period (20,704 ) 1 (20,703 ) 9,750 0 9,750 Net loss reclassified into income (1) 20,700 0 20,700 0 0 0 Net change in unrealized gains (losses) on available for sale securities (4 ) 1 (3 ) 9,750 0 9,750 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 16 (6 ) 10 971 (382 ) 589 Net (gains) losses reclassified into income (708 ) 276 (432 ) (285 ) 112 (173 ) Net change in unrealized (losses) gains on foreign exchange contracts (692 ) 270 (422 ) 686 (270 ) 416 Net (loss) gain on cash flow hedges (692 ) 270 (422 ) 686 (270 ) 416 Other comprehensive income (loss) $ (3 ) $ 271 $ 268 $ 10,586 $ (270 ) $ 10,316 ____________________________________________ (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our divestiture of the NantHealth common stock. Nine Months Ended September 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 3,040 $ 0 $ 3,040 $ (49 ) $ 0 $ (49 ) Available for sale securities: Net loss arising during the period (106,358 ) 3 (106,355 ) (8,365 ) 0 (8,365 ) Net loss reclassified into income (1) 162,865 0 162,865 0 0 0 Net change in unrealized gains (losses) on available for sale securities 56,507 3 56,510 (8,365 ) 0 (8,365 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,323 (902 ) 1,421 1,172 (462 ) 710 Net (gains) losses reclassified into income (1,982 ) 773 (1,209 ) (272 ) 107 (165 ) Net change in unrealized gains (losses) on foreign exchange contracts 341 (129 ) 212 900 (355 ) 545 Net gain (loss) on cash flow hedges 341 (129 ) 212 900 (355 ) 545 Other comprehensive income (loss) $ 59,888 $ (126 ) $ 59,762 $ (7,514 ) $ (355 ) $ (7,869 ) ____________________________________________ (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our divestiture of the NantHealth common stock.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us alleging violations of the Telephone Consumer Protection Act (the “TCPA”). On June 2, 2017, the court denied Allscripts’ motion for summary judgment, and also denied Plaintiff’s motion for class certification. Plaintiff did not seek appellate review of the Court’s denial of class certification, so the only claim remaining in the case is Plaintiff’s individual TCPA claim. On August 11, 2017, Plaintiff filed a motion for summary judgment against Allscripts. On September 25, the court stayed this matter pending the outcome of the appeal in Brodsky v. Humana Dental Ins. Co. The EIS Business acquired from McKesson on October 2, 2017 (as discussed below under Note 15, “Subsequent Events”) is subject to a May 2017 civil investigative demand (CID) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the CID, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition.

Business Segments

Business Segments	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Business Segments	13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. As of September 30, 2017, we had eight operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the Ambulatory, Hospitals and Health Systems, previously named “Acute”, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of four separate operating segments: Population Health, FollowMyHealth ® TM Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The historical results of our Homecare TM Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Revenue: Clinical and Financial Solutions $ 303,323 $ 276,503 $ 870,452 $ 830,200 Population Health 60,515 61,722 179,313 170,803 Netsmart 83,618 52,621 235,046 96,854 Unallocated Amounts 1,986 1,538 4,197 26,606 Total revenue $ 449,442 $ 392,384 $ 1,289,008 $ 1,124,463 Gross Profit: Clinical and Financial Solutions $ 130,224 $ 113,677 $ 363,228 $ 349,017 Population Health 41,947 46,337 125,535 125,152 Netsmart 39,644 17,378 111,489 32,327 Unallocated Amounts (9,896 ) (11,233 ) (32,190 ) (21,755 ) Total gross profit $ 201,919 $ 166,159 $ 568,062 $ 484,741 Income (loss) from operations: Clinical and Financial Solutions $ 68,837 $ 59,921 $ 186,846 $ 188,145 Population Health 29,298 32,977 86,282 81,895 Netsmart 7,153 (6,426 ) 23,910 (8,825 ) Unallocated Amounts (79,915 ) (69,598 ) (239,298 ) (213,871 ) Total income from operations $ 25,373 $ 16,874 $ 57,740 $ 47,344

Supplemental Disclosures

Supplemental Disclosures	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	14. Supplemental Disclosures Restricted Cash The majority of the restricted cash balance as of September 30, 2017 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements. Nine Months Ended September 30, (In thousands) 2017 2016 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 104,301 $ 76,636 Restricted cash 5,123 615 Total cash, cash equivalents and restricted cash $ 109,424 $ 77,251 Supplemental non-cash information: Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management $ 0 $ 25,543 Exchange of NantHealth, Inc. common stock for net assets acquired of provider/patient solutions business $ 42,750 $ 0 Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 32,887 $ 18,344 Obligations incurred to purchase capitalized software or enter into capital leases $ 11,515 $ 0 Issuance of treasury stock to commercial partner $ 334 $ 0

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On October 2, 2017, Allscripts Healthcare, LLC, a wholly-owned subsidiary of the Company (“Healthcare LLC”), completed the transactions contemplated by a purchase agreement (the “Purchase Agreement”) with McKesson Corporation (“McKesson”), pursuant to which Healthcare LLC purchased McKesson’s Enterprise Information Solutions Business division (the “EIS Business”), which provides certain software solutions and services to hospitals and health systems, by acquiring all of the outstanding equity interests of two indirect, wholly-owned subsidiaries of McKesson for a purchase price of $185 million, subject to adjustments for net working capital and net debt. The purchase price was funded through incremental borrowings under our debt facilities. The financial results of the EIS Business will be consolidated with our financial results starting on the date of the transaction. As of the date of this Form 10-Q, the preliminary allocation of the fair value of the consideration transferred has not yet been completed

Basis of Presentation and Sig22

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2017 and 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have decided to adopt the standard effective January 1, 2018 using the modified retrospective method. We have completed our assessment of our systems, available data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Through evaluation of the standard’s requirements, the Company plans to utilize several practical expedients including (i) viewing shipping and handling as a fulfillment cost versus a distinct performance obligation, and (ii) the right to invoice expedient as it relates to transaction-related revenue activities. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware sales, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscription contracts that include both software licenses and software support and maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue license recognition treatment required under the new standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. Additionally, we currently only capitalize direct sales commissions that are specifically associated with new or renewal contracts. The new revenue recognition guidance requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. As part of our implementation efforts, we have identified certain indirect commissions and other payments that would be eligible for capitalization under the new guidance because they are also incremental costs solely associated with new or renewal contracts that we expect to recover. As result, we expect to record a deferral for such costs, which could be significant, upon adoption of the new guidance on January 1, 2018. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2017
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	Total consideration for the transaction was as follows: (In thousands) Cash $ 1,742 NantHealth common stock 42,750 Less: Value assigned to modification of existing commercial agreement with NantHealth (22,700 ) Total consideration for NantHealth provider/patient solutions business $ 21,792
Schedule of Supplemental Proforma Results	The below supplemental pro forma data for the combined entity is presented under the assumption that the Netsmart and HealthMEDX acquisitions occurred on January 1, 2015 and the NantHealth provider/patient solutions business acquisition occurred on January 1, 2016. The three and nine months ended September 30, 2017 only reflect pro forma adjustments related to the NantHealth provider/patient solutions business, as Netsmart and HealthMEDX are included for the full 2017 periods. (In thousands, except per share amounts) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 52,621 $ 96,855 Net loss $ (11,126 ) $ (18,239 ) Actual from NantHealth since acquisition date of August 25, 2017: Revenue $ 648 $ 0 $ 648 $ 0 Net loss $ (628 ) $ 0 $ (628 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 451,142 $ 1,296,008 $ 403,741 $ 1,229,471 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (27,260 ) $ (223,449 ) $ (14,799 ) $ (66,220 ) Loss per share, basic and diluted $ (0.15 ) $ (1.24 ) $ (0.08 ) $ (0.35 )
NantHealth, Inc. [Member]
Assets Acquired and Liabilities Assumed	The allocation of the fair value of the consideration transferred as of the acquisition date of August 25, 2017 is shown in the table below. (In thousands) Cash and cash equivalents $ 21 Accounts receivable, net 2,078 Prepaid expenses and other current assets 1,806 Fixed assets 7,099 Intangible assets 12,400 Goodwill 9,058 Other assets 205 Accounts payable and accrued expenses (1,575 ) Deferred revenue (9,300 ) Net assets acquired $ 21,792
Acquired Intangible Assets Amortization	The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 19 $ 9,200 Technology 5 3,000 Tradenames 5 200 $ 12,400

Fair Value Measurements and L24

Fair Value Measurements and Long-term Investments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 0 $ 0 $ 0 $ 0 $ 149,100 $ 0 $ 0 $ 149,100 1.25% Call Option Other assets 0 0 44,882 44,882 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (45,973 ) (45,973 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 1,362 0 1,362 0 1,021 0 1,021 Total $ 0 $ 1,362 $ (1,091 ) $ 271 $ 149,100 $ 1,021 $ (579 ) $ 149,542
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at September 30, 2017 Investment September 30, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 4,142 $ 2,436 Cost method investments 7 32,784 26,572 26,041 Total equity investments 10 $ 34,442 $ 30,714 $ 28,477 _________________________________ (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 378 $ 979 $ 2,491 $ 3,209 Client services 899 884 3,464 3,512 Total cost of revenue 1,277 1,863 5,955 6,721 Selling, general and administrative expenses 7,193 6,464 17,793 17,972 Research and development 1,934 1,446 6,643 6,141 Total stock-based compensation expense $ 10,404 $ 9,773 $ 30,391 $ 30,834
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 11 $ 13.73 1,908 $ 12.38 Performance-based restricted stock units with a service condition 38 $ 13.25 610 $ 12.01 Market-based restricted stock units with a service condition 0 $ 0.00 613 $ 13.34 49 $ 13.36 3,131 $ 12.50
Netsmart [Member]
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 42 $ 31 $ 17 $ 56 Client services 56 33 (12 ) 70 Total cost of revenue 98 64 5 126 Selling, general and administrative expenses 2,302 1,617 (557 ) 2,945 Research and development 63 43 (13 ) 79 Total stock-based compensation expense (benefit) $ 2,463 $ 1,724 $ (565 ) $ 3,150

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2017 2016 2017 2016 Basic Loss per Common Share: Net (loss) income $ (17,462 ) $ 157 $ (169,038 ) $ 148 Less: Net income attributable to non-controlling interests (163 ) (151 ) (352 ) (142 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,962 ) (10,191 ) (32,887 ) (18,344 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (28,587 ) $ (10,185 ) $ (202,277 ) $ (18,338 ) Weighted-average common shares outstanding 180,634 186,226 180,864 187,190 Basic Loss per Common Share $ (0.16 ) $ (0.06 ) $ (1.12 ) $ (0.10 ) Diluted Loss per Common Share: Net (loss) income $ (17,462 ) $ 157 $ (169,038 ) $ 148 Less: Net income attributable to non-controlling interests (163 ) (151 ) (352 ) (142 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (10,962 ) (10,191 ) (32,887 ) (18,344 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (28,587 ) $ (10,185 ) $ (202,277 ) $ (18,338 ) Weighted-average common shares outstanding 180,634 186,226 180,864 187,190 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 180,634 186,226 180,864 187,190 Diluted Loss per Common Share $ (0.16 ) $ (0.06 ) $ (1.12 ) $ (0.10 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,085 27,580 26,636 26,219

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: September 30, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 638,118 $ (388,913 ) $ 249,205 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 843,458 (454,430 ) 389,028 813,021 (430,960 ) 382,061 Total $ 1,481,576 $ (843,343 ) $ 638,233 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,971,950 1,924,052 Total $ 2,050,950 $ 2,003,052
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 DeVero acquisition 0 0 32,943 32,943 Nanthealth provider/patient solutions business 0 9,058 0 9,058 Other additions 405 47 4,503 4,955 Foreign exchange translation 942 0 0 942 Balance as of September 30, 2017 $ 845,184 $ 413,980 $ 712,786 $ 1,971,950

Asset and Long-term Investmen28

Asset and Long-term Investment Impairment Charges (Tables)	9 Months Ended
	Sep. 30, 2017
Asset And Long Term Investment Impairment Charges [Abstract]
Asset and Long-term Investment Impairment Charges	We incurred the following asset and long-term investment impairment charges: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Asset impairment charges $ 0 $ 0 $ 0 $ 4,650 Impairment of and losses on long-term investments $ 20,700 $ 0 $ 165,290 $ 0

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consists of the following: September 30, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 39,319 $ 305,681 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 470,000 3,690 466,310 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 480,533 11,482 469,051 432,925 11,655 421,270 Second Lien Term Loan 167,000 7,789 159,211 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,462,533 $ 62,280 $ 1,400,253 $ 1,386,813 $ 74,433 $ 1,312,380 Less: Debt payable within one year - excluding Netsmart 25,000 450 24,550 15,638 480 15,158 Less: Debt payable within one year - Netsmart 4,866 2,117 2,749 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,432,667 $ 59,713 $ 1,372,954 $ 1,366,824 $ 72,053 $ 1,294,771
Interest Expense	Interest expense consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Interest expense $ 5,577 $ 3,896 $ 15,079 $ 11,029 Amortization of discounts and debt issuance costs 3,674 3,522 10,867 10,401 Netsmart: Interest expense (1) 12,107 11,019 34,188 19,549 Amortization of discounts and debt issuance costs 894 930 2,588 1,778 Total interest expense $ 22,252 $ 19,367 $ 62,722 $ 42,757 (1) Includes interest expense related to capital leases.
Summary of Future Debt Payment Obligations	The following table summarizes future debt payment obligations as of September 30, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 225,000 6,250 28,125 40,625 150,000 0 0 Revolving Facility (2) 245,000 0 0 0 245,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 480,533 1,217 4,866 4,866 4,866 4,866 459,852 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,462,533 $ 7,467 $ 32,991 $ 45,491 $ 744,866 $ 4,866 $ 626,852 (1) (2)
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 1.25% Notes	Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 3,234 $ 3,234 Amortization of discounts and debt issuance costs 3,342 3,185 9,866 9,401 Total interest expense related to the 1.25% Notes $ 4,420 $ 4,263 $ 13,100 $ 12,635

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 (Loss) income before income taxes $ (17,700 ) $ (2,499 ) $ (170,111 ) $ (2,448 ) Income tax benefit (provision) $ 238 $ 2,656 $ 1,073 $ 2,596 Effective tax rate 1.3 % 106.3 % 0.6 % 106.0 %

Derivative Financial Instrume31

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,362 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 44,882 N/A 1.25% Embedded cash conversion option N/A Other liabilities 45,973 Total derivatives $ 46,244 $ 45,973 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Foreign exchange contracts $ 16 $ 2,323 Cost of Revenue $ 241 $ 674 Selling, general and administrative expenses 184 515 Research and development $ 283 $ 793 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Foreign exchange contracts $ 971 $ 1,172 Cost of Revenue $ 88 $ 84 Selling, general and administrative expenses 71 68 Research and development $ 126 $ 120
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 1.25% Call Option $ 12,837 $ 2,306 $ 27,802 $ (39,404 ) 1.25% Embedded cash conversion option (13,043 ) (2,362 ) (28,314 ) 39,609 Net (loss) gain included in other income, net $ (206 ) $ (56 ) $ (512 ) $ 205

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net (Losses) Gains on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (1) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive income (loss) before reclassifications 3,040 (106,355 ) 1,421 (101,894 ) Net losses (gains) reclassified from accumulated other comprehensive loss (2) 0 162,865 (1,209 ) 161,656 Net other comprehensive income 3,040 56,510 212 59,762 Balance as of September 30, 2017 (3) $ (2,988 ) $ 90 $ 831 $ (2,067 ) ______________________________________________________ (1) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. (2) Reclassification adjustment related to other-than-temporary impairment and loss on disposition of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our disposition of the NantHealth common stock. (3) Net of taxes of $531 thousand for unrealized net gains on foreign exchange contract derivatives and $58 thousand for unrealized net gains on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (49 ) (8,365 ) 710 (7,704 ) Net losses reclassified from accumulated other comprehensive loss 0 0 (165 ) (165 ) Net other comprehensive (loss) income (49 ) (8,365 ) 545 (7,869 ) Balance as of September 30, 2016 (2) $ (4,549 ) $ (8,365 ) $ 803 $ (12,111 ) ____________________________________________________________________________ (1) (2) Net of taxes of $
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 693 $ 0 $ 693 $ 150 $ 0 $ 150 Available for sale securities: Net loss arising during the period (20,704 ) 1 (20,703 ) 9,750 0 9,750 Net loss reclassified into income (1) 20,700 0 20,700 0 0 0 Net change in unrealized gains (losses) on available for sale securities (4 ) 1 (3 ) 9,750 0 9,750 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 16 (6 ) 10 971 (382 ) 589 Net (gains) losses reclassified into income (708 ) 276 (432 ) (285 ) 112 (173 ) Net change in unrealized (losses) gains on foreign exchange contracts (692 ) 270 (422 ) 686 (270 ) 416 Net (loss) gain on cash flow hedges (692 ) 270 (422 ) 686 (270 ) 416 Other comprehensive income (loss) $ (3 ) $ 271 $ 268 $ 10,586 $ (270 ) $ 10,316 ____________________________________________ (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our divestiture of the NantHealth common stock. Nine Months Ended September 30, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 3,040 $ 0 $ 3,040 $ (49 ) $ 0 $ (49 ) Available for sale securities: Net loss arising during the period (106,358 ) 3 (106,355 ) (8,365 ) 0 (8,365 ) Net loss reclassified into income (1) 162,865 0 162,865 0 0 0 Net change in unrealized gains (losses) on available for sale securities 56,507 3 56,510 (8,365 ) 0 (8,365 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,323 (902 ) 1,421 1,172 (462 ) 710 Net (gains) losses reclassified into income (1,982 ) 773 (1,209 ) (272 ) 107 (165 ) Net change in unrealized gains (losses) on foreign exchange contracts 341 (129 ) 212 900 (355 ) 545 Net gain (loss) on cash flow hedges 341 (129 ) 212 900 (355 ) 545 Other comprehensive income (loss) $ 59,888 $ (126 ) $ 59,762 $ (7,514 ) $ (355 ) $ (7,869 ) ____________________________________________ (1) Reclassification adjustment related to other-than-temporary impairment of our investment in NantHealth. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 7, “Asset and Long-term Investment Impairment Charges,” for further information regarding this impairment. Refer to Note 2, “Business Combinations,” for information regarding our divestiture of the NantHealth common stock.

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2017 2016 2017 2016 Revenue: Clinical and Financial Solutions $ 303,323 $ 276,503 $ 870,452 $ 830,200 Population Health 60,515 61,722 179,313 170,803 Netsmart 83,618 52,621 235,046 96,854 Unallocated Amounts 1,986 1,538 4,197 26,606 Total revenue $ 449,442 $ 392,384 $ 1,289,008 $ 1,124,463 Gross Profit: Clinical and Financial Solutions $ 130,224 $ 113,677 $ 363,228 $ 349,017 Population Health 41,947 46,337 125,535 125,152 Netsmart 39,644 17,378 111,489 32,327 Unallocated Amounts (9,896 ) (11,233 ) (32,190 ) (21,755 ) Total gross profit $ 201,919 $ 166,159 $ 568,062 $ 484,741 Income (loss) from operations: Clinical and Financial Solutions $ 68,837 $ 59,921 $ 186,846 $ 188,145 Population Health 29,298 32,977 86,282 81,895 Netsmart 7,153 (6,426 ) 23,910 (8,825 ) Unallocated Amounts (79,915 ) (69,598 ) (239,298 ) (213,871 ) Total income from operations $ 25,373 $ 16,874 $ 57,740 $ 47,344

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Reconciliation of Cash and Cash Equivalent, Restricted Cash and Supplemental Non-Cash Information	The majority of the restricted cash balance as of September 30, 2017 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements. Nine Months Ended September 30, (In thousands) 2017 2016 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 104,301 $ 76,636 Restricted cash 5,123 615 Total cash, cash equivalents and restricted cash $ 109,424 $ 77,251 Supplemental non-cash information: Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management $ 0 $ 25,543 Exchange of NantHealth, Inc. common stock for net assets acquired of provider/patient solutions business $ 42,750 $ 0 Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 32,887 $ 18,344 Obligations incurred to purchase capitalized software or enter into capital leases $ 11,515 $ 0 Issuance of treasury stock to commercial partner $ 334 $ 0

Basis of Presentation and Sig35

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017
ASU 2016-09 [Member]
Summary Of Significant Accounting Policy [Line Items]
Decrease in accumulated deficit due to the recognition of excess tax benefit after valuation allowance	$ 1.8	$ 1.8

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 25, 2017	Jul. 17, 2017	Oct. 27, 2016	Apr. 19, 2016	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Cash paid for business acquisitions						$ 54,308	$ 935,280
Goodwill						$ 1,971,950		$ 1,924,052
Contribution and investment agreement date						Mar. 20, 2016
Increase in goodwill from subsequent adjustment of liability						$ 9,058
Homecare Business [Member]
Business Acquisition [Line Items]
Escrow deposit related to the integration of homecare business				$ 15,000		11,300
Escrow deposit period				5 years
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Goodwill					$ 4,400
Asset purchase agreement date					Mar. 31, 2017
Aggregate cash consideration to acquire intellectual property, certain contractual relationships and certain associates					$ 4,000
Business combination, estimated consideration payable					700
Contingent consideration, fair value						500
NantHealth, Inc. [Member]
Business Acquisition [Line Items]
Goodwill	$ 9,058
Acquired cash and cash equivalents, and restricted cash	21
Liabilities assumed, deferred revenue	$ 9,300
Number of shares as consideration for asset purchase agreement	15,000,000
Aggregate consideration with a fair value	$ 42,750
Business combination, aggregate consideration	$ 21,792
NantHealth, Inc. [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets						$ 9,200
Intangible assets, useful life (in years)						19 years
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date						Apr. 19, 2016
HealthMEDX, LLC [Member]
Business Acquisition [Line Items]
Date of acquisition			Oct. 27, 2016
Business combination, aggregate consideration			$ 39,200
Business combination, adjustment of fair value of liability					100
Increase in goodwill from subsequent adjustment of liability					$ 100
Netsmart [Member]
Business Acquisition [Line Items]
Goodwill						$ 712,786		$ 675,340
Increase in goodwill from subsequent adjustment of liability						$ 0
Netsmart [Member] | DeVero, Inc. [Member]
Business Acquisition [Line Items]
Cash paid for business acquisitions		$ 50,700
Goodwill		32,900
Acquired cash and cash equivalents, and restricted cash		2,000
Assets acquired, other operating assets		1,500
Liabilities assumed, accounts payable and accrued expenses		2,300
Liabilities assumed, deferred revenue		900
Liabilities assumed, deferred tax liabilities net		8,400
Date of acquisition						Jul. 17, 2017
Goodwill, expected tax deductible amount		0
Netsmart [Member] | DeVero, Inc. [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets		19,000
Intangible assets, useful life (in years)						7 years
Netsmart [Member] | DeVero, Inc. [Member] | Technology [Member]
Business Acquisition [Line Items]
Intangible assets		$ 6,900
Intangible assets, useful life (in years)						20 years

Schedule of Consideration Trans

Schedule of Consideration Transaction (Detail) - NantHealth, Inc. [Member] $ in Thousands	Aug. 25, 2017USD ($)
Business Acquisition [Line Items]
Cash	$ 1,742
NantHealth common stock	42,750
Less: Value assigned to modification of existing commercial agreement with NantHealth	(22,700)
Total consideration for NantHealth provider/patient solutions business	$ 21,792

Assets Acquired and Liabilities

Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Aug. 25, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 1,971,950		$ 1,924,052
NantHealth, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 21
Accounts receivable, net		2,078
Prepaid expenses and other current assets		1,806
Fixed assets		7,099
Intangible assets	$ 12,400	12,400
Goodwill		9,058
Other assets		205
Accounts payable and accrued expenses		(1,575)
Deferred revenue		(9,300)
Net assets acquired		$ 21,792

Acquired Intangible Assets Amor

Acquired Intangible Assets Amortization (Detail) - NantHealth, Inc. [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Aug. 25, 2017
Business Acquisition [Line Items]
Intangible assets	$ 12,400	$ 12,400
Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	19 years
Intangible assets, fair value	$ 9,200
Technology [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	5 years
Intangible assets, fair value	$ 3,000
Tradenames [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	5 years
Intangible assets, fair value	$ 200

Pro forma Results (Detail)

Pro forma Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Netsmart [Member]
Business Acquisition [Line Items]
Revenue		$ 52,621		$ 96,855
Net loss		(11,126)		(18,239)
NantHealth, Inc. [Member]
Business Acquisition [Line Items]
Revenue	$ 648,000	648,000	$ 0	0
Net loss	(628,000)	(628,000)	0	0
Combined Entity [Member]
Business Acquisition [Line Items]
Revenue	451,142	403,741	1,296,008	1,229,471
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (27,260)	$ (14,799)	$ (223,449)	$ (66,220)
Loss per share, basic and diluted	$ (0.15)	$ (0.08)	$ (1.24)	$ (0.35)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	$ 0	$ 149,100
Prepaid expenses and other current assets	115,701	102,551
Total	271	149,542
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,362	1,021
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(45,973)	(17,659)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	44,882	17,080
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	149,100
Total	0	149,100
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	1,362	1,021
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,362	1,021
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	(1,091)	(579)
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(45,973)	(17,659)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 44,882	$ 17,080

Summary of Long-term Equity Inv

Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		9 Months Ended
		Sep. 30, 2017USD ($)Investment	Dec. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	3
Cost method investments, Number of Investees | Investment		7
Total equity investments, Number of Investees | Investment		10
Equity method investments, Original Investment	[1]	$ 1,658
Cost method investments, Original Investment		32,784
Total equity investments, Original Investment		34,442
Equity method investments, Carrying Value		4,142	$ 2,436
Cost method investments, Carrying Value		26,572	26,041
Total equity investments, Carrying Value		$ 30,714	$ 28,477
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and L43

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2017
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other-than-temporary impairment charges on available for sale marketable securities		$ 142.2
Available for sale marketable securities cost basis	$ 205.6		$ 205.6
Loss on final disposition of securities	$ (20.7)
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%		1.25%
Equity Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other-than-temporary impairment charges on cost method equity investments			$ 2.1
Aggregate carrying value of cost method investments prior to impairment charges	$ 2.1		$ 2.1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Nov. 17, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0	$ 0	$ 0
Stock options granted	0	0	0	0
Share issued, exercise of options and release of stock awards			1,200,000		1,500,000
Shares settled for tax withholding			569,000	572,000
Common stock repurchased, amount			$ 12,077,000	$ 71,082,000
Netsmart [Member]
Class Of Stock [Line Items]
Stock options granted	3,300		3,300
Liability for outstanding awards	$ 5,200,000		$ 5,200,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model	$ 0.23		$ 0.23		$ 0.54
Stock options granted, exercise price			$ 1
Netsmart [Member] | Time Based Option Unit Awards [Member]
Class Of Stock [Line Items]
Stock options granted			2,100
Netsmart [Member] | Performance Based Option Unit Awards [Member]
Class Of Stock [Line Items]
Stock options granted			1,200
November 2016 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 200,000,000
Common stock repurchased, shares	0		1,000,000
Common stock repurchased, amount	$ 12,100,000		$ 12,100,000
Approximate value of common stock shares yet to be purchased under the stock repurchase program	$ 163,900,000		$ 163,900,000

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 10,404	$ 9,773	$ 30,391	$ 30,834
Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	2,463	1,724	(565)	3,150
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,277	1,863	5,955	6,721
Cost of revenue [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	98	64	5	126
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	378	979	2,491	3,209
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	42	31	17	56
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	899	884	3,464	3,512
Cost of revenue [Member] | Client services [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	56	33	(12)	70
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	7,193	6,464	17,793	17,972
Selling, General and Administrative Expenses [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	2,302	1,617	(557)	2,945
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,934	1,446	6,643	6,141
Research and development [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense (benefit)	$ 63	$ 43	$ (13)	$ 79

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	49	3,131
Weighted-Average Grant Date Fair Value, granted	$ 13.36	$ 12.50
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	11	1,908
Weighted-Average Grant Date Fair Value, granted	$ 13.73	$ 12.38
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	38	610
Weighted-Average Grant Date Fair Value, granted	$ 13.25	$ 12.01
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	613
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 13.34

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Basic Loss per Common Share:
Net (loss) income	$ (17,462)	$ 157	$ (169,038)	$ 148
Less: Net income attributable to non-controlling interests	(163)	(151)	(352)	(142)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	(10,191)	(32,887)	(18,344)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (28,587)	$ (10,185)	$ (202,277)	$ (18,338)
Weighted-average common shares outstanding	180,634	186,226	180,864	187,190
Basic Loss per Common Share	$ (0.16)	$ (0.06)	$ (1.12)	$ (0.10)
Diluted Loss per Common Share:
Net (loss) income	$ (17,462)	$ 157	$ (169,038)	$ 148
Less: Net income attributable to non-controlling interests	(163)	(151)	(352)	(142)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	(10,191)	(32,887)	(18,344)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (28,587)	$ (10,185)	$ (202,277)	$ (18,338)
Weighted-average common shares outstanding	180,634	186,226	180,864	187,190
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	180,634	186,226	180,864	187,190
Diluted Loss per Common Share	$ (0.16)	$ (0.06)	$ (1.12)	$ (0.10)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	26,085	27,580	26,636	26,219

Goodwill and Intangible Asset49

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,481,576	$ 1,440,840
Accumulated Amortization	(843,343)	(778,437)
Intangible Assets, Net	638,233	662,403
Registered trademarks	79,000	79,000
Goodwill	1,971,950	1,924,052
Total	2,050,950	2,003,052
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	638,118	627,819
Accumulated Amortization	(388,913)	(347,477)
Intangible Assets, Net	249,205	280,342
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	843,458	813,021
Accumulated Amortization	(454,430)	(430,960)
Intangible Assets, Net	$ 389,028	$ 382,061

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill [Line Items]
Goodwill	$ 1,924,052
DeVero acquisition	32,943
Nanthealth provider/patient solutions business	9,058
Other additions	4,955
Foreign exchange translation	942
Goodwill, net	1,971,950
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	843,837
DeVero acquisition	0
Nanthealth provider/patient solutions business	0
Other additions	405
Foreign exchange translation	942
Goodwill, net	845,184
Population Health [Member]
Goodwill [Line Items]
Goodwill	404,875
DeVero acquisition	0
Nanthealth provider/patient solutions business	9,058
Other additions	47
Foreign exchange translation	0
Goodwill, net	413,980
Netsmart [Member]
Goodwill [Line Items]
Goodwill	675,340
DeVero acquisition	32,943
Nanthealth provider/patient solutions business	0
Other additions	4,503
Foreign exchange translation	0
Goodwill, net	$ 712,786

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Schedule Of Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses associated with goodwill	$ 0	$ 0	$ 0
Additions		$ 32,943,000
NantHealth, Inc. [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions	9,100,000
DeVero, Inc. [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions	$ 32,900,000

Asset and Long-term Investmen52

Asset and Long-term Investment Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Asset And Long Term Investment Impairment Charges [Abstract]
Asset impairment charges	$ 0	$ 0	$ 0	$ 4,650
Impairment of and losses on long-term investments	$ 20,700	$ 0	$ 165,290	$ 0

Asset and Long-term Investmen53

Asset and Long-term Investment Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges	$ 0		$ 0		$ 0	$ 4,650
Other charges				$ 400
Other than temporary impairment charges on long-term Investments	$ 20,700	$ 144,600			$ 165,290	$ 0
Capitalized Software Development Projects [Member]
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges				2,200
Cost Method Equity Investments [Member]
Asset and Long-term Investment Impairment Charges [Line Items]
Asset impairment charges				$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Principal Balance	$ 1,462,533		$ 1,386,813
Unamortized Discount and Debt Issuance Costs	62,280		74,433
Net Carrying Amount	1,400,253		1,312,380
Principal Balance, Current	25,000		15,638
Unamortized Discount and Debt Issuance Costs, Current	450		480
Net Carrying Amount, Current	24,550		15,158
Principal Balance, Noncurrent	1,432,667		1,366,824
Unamortized Discount and Debt Issuance Costs, Noncurrent	59,713		72,053
Net Carrying Amount, Noncurrent	1,372,954		1,294,771
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	4,866		4,351
Unamortized Discount and Debt Issuance Costs, Current	2,117		1,900
Net Carrying Amount, Current	2,749		2,451
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	39,319		49,186
Net Carrying Amount	305,681		295,814
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	470,000		441,875
Unamortized Discount and Debt Issuance Costs	3,690		4,691
Net Carrying Amount	466,310		437,184
Netsmart Non-Recourse Debt First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	480,533		432,925
Unamortized Discount and Debt Issuance Costs	11,482		11,655
Net Carrying Amount	469,051		421,270
Netsmart Non-Recourse Debt Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		167,000
Unamortized Discount and Debt Issuance Costs	7,789		8,901
Net Carrying Amount	159,211		158,099
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	0		13
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 0		$ 13
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Total interest expense		$ 22,252	$ 19,367	$ 62,722	$ 42,757
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense		5,577	3,896	15,079	11,029
Amortization of discounts and debt issuance costs		3,674	3,522	10,867	10,401
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		894	930	2,588	1,778
Interest expense	[1]	$ 12,107	$ 11,019	$ 34,188	$ 19,549
[1]	Includes interest expense related to capital leases.

Interest Expense Related to 1.2

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078	$ 3,234	$ 3,234
Amortization of discounts and debt issuance costs	3,342	3,185	9,866	9,401
Total interest expense related to the 1.25% Notes	$ 4,420	$ 4,263	$ 13,100	$ 12,635

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)		Oct. 02, 2017	Sep. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Debt instrument principal amount			$ 1,462,533,000		$ 1,386,813,000
Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			6.08%
LIBOR Rate [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			4.75%
Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	[1]		$ 225,000,000
Allscripts Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			245,000,000
Letters of credit outstanding			800,000
Credit facility, amount available			$ 304,200,000
Allscripts Senior Secured Revolving Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt instrument additional borrowings		$ 185,000,000
Allscripts Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			3.49%
Allscripts Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			2.25%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 345,000,000	[2]	$ 345,000,000
Interest rate			1.25%
Netsmart First Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 0
Letters of credit outstanding			0
Credit facility, amount available			50,000,000
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 480,500,000
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			10.82%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 167,000,000
Netsmart Second Lien Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			9.50%
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 480,533,000
Debt instrument, interest rate, effective percentage			5.83%
Netsmart First Lien Term Loan [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate			4.50%
[1]	Assumes no additional borrowings after September 30, 2017, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.
[2]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Debt Payment

Summary of Future Debt Payment Obligations (Detail) - USD ($) $ in Thousands		Sep. 30, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Total		$ 1,462,533		$ 1,386,813
Remainder of 2017		7,467
2,018		32,991
2,019		45,491
2,020		744,866
2,021		4,866
Thereafter		626,852
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	$ 345,000
Remainder of 2017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
2,021	[1]	0
Thereafter	[1]	0
Term Loan [Member]
Debt Instrument [Line Items]
Total	[2]	225,000
Remainder of 2017	[2]	6,250
2,018	[2]	28,125
2,019	[2]	40,625
2,020	[2]	150,000
2,021	[2]	0
Thereafter	[2]	0
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		480,533
Remainder of 2017		1,217
2,018		4,866
2,019		4,866
2,020		4,866
2,021		4,866
Thereafter		459,852
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000
Remainder of 2017		0
2,018		0
2,019		0
2,020		0
2,021		0
Thereafter		167,000
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	[2]	245,000
Remainder of 2017	[2]	0
2,018	[2]	0
2,019	[2]	0
2,020	[2]	245,000
2,021	[2]	0
Thereafter	[2]	$ 0
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.
[2]	Assumes no additional borrowings after September 30, 2017, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Summary of Future Debt Paymen59

Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2017
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
(Loss) income before income taxes	$ (17,700)	$ (2,499)	$ (170,111)	$ (2,448)
Income tax benefit (provision)	$ 238	$ 2,656	$ 1,073	$ 2,596
Effective tax rate	1.30%	106.30%	0.60%	106.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance		$ 64.2
Cumulative operating income loss period considered		3 years
Unrecognized income tax benefits		$ 12	$ 11.4
ASU 2016-09 [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax expense on compensation cost	$ 1.5
Change in valuation allowance from offsetting release	(1.5)
Cumulative effect adjustment on accumulated deficit, gross	5.6
Decrease in accumulated deficit due to the recognition of excess tax benefit after valuation allowance	1.8	1.8
Valuation allowance recognized	$ 3.8
Valuation Allowance of Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance related to deferred tax assets from operating loss carryforwards		$ 67.8

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 46,244	$ 18,101
Derivative liability, fair value	45,973	17,659
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	1,362	1,021
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	44,882	17,080
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 45,973	$ 17,659

Derivative Financial Instrume63

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)Derivative	Sep. 30, 2017USD ($)Derivative	Sep. 30, 2017INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	9	9	9
Derivative notional amount outstanding	$ 1,800,000	$ 1,800,000	₨ 120,000,000
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0	0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	$ 1,400,000	$ 1,400,000
Estimated period of unrealized gains included in AOCI reclassified into income		12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature		Oct. 31, 2017
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature		Jun. 30, 2018
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option				$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 16	$ 971	$ 2,323	$ 1,172
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	241	88	674	84
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	184	71	515	68
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 283	$ 126	$ 793	$ 120

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ (206)	$ (56)	$ (512)	$ 205
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	12,837	2,306	27,802	(39,404)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ (13,043)	$ (2,362)	$ (28,314)	$ 39,609

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,232,466
Total other comprehensive income (loss)	$ 268	$ 10,316	59,762	$ (7,869)
Balance at the end of the period	1,105,394		1,105,394
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(6,028)	(4,500)
Other comprehensive income (loss) before reclassifications			3,040	(49)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive income (loss)			3,040	(49)
Balance at the end of the period	(2,988)	(4,549)	(2,988)	(4,549)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(56,420)	0
Other comprehensive income (loss) before reclassifications			(106,355)	(8,365)
Net losses (gains) reclassified from accumulated other comprehensive loss			162,865	0
Total other comprehensive income (loss)			56,510	(8,365)
Balance at the end of the period	90	(8,365)	90	(8,365)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			619	258
Other comprehensive income (loss) before reclassifications			1,421	710
Net losses (gains) reclassified from accumulated other comprehensive loss			(1,209)	(165)
Total other comprehensive income (loss)			212	545
Balance at the end of the period	831	803	831	803
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(61,829)	(4,242)
Other comprehensive income (loss) before reclassifications			(101,894)	(7,704)
Net losses (gains) reclassified from accumulated other comprehensive loss			161,656	(165)
Total other comprehensive income (loss)			59,762	(7,869)
Balance at the end of the period	$ (2,067)	$ (12,111)	$ (2,067)	$ (12,111)

Components of Accumulated Oth67

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 58	$ 61
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 531	$ 402	$ 521	$ 166

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 693	$ 150	$ 3,040	$ (49)
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	(4)	9,750	56,507	(8,365)
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(692)	686	341	900
Other comprehensive (loss) income, Before-Tax Amount	(3)	10,586	59,888	(7,514)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive (loss) income, Tax Effect	271	(270)	(126)	(355)
Foreign currency translation adjustments, Net	693	150	3,040	(49)
Other comprehensive (loss) income, Net	268	10,316	59,762	(7,869)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Available for sale securities, net loss arising during the period, Before-Tax Amount	(20,704)	9,750	(106,358)	(8,365)
Available for sale securities, net loss reclassified into income, Before-Tax Amount	20,700	0	162,865	0
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	(4)	9,750	56,507	(8,365)
Available for sale securities, net loss arising during the period, Tax Effect	1	0	3	0
Available for sale securities, net loss reclassified into income, Tax Effect	0	0	0	0
Net change in unrealized gains (losses) on available for sale securities, Tax Effect	1	0	3	0
Available for sale securities, net loss arising during the period, Net	(20,703)	9,750	(106,355)	(8,365)
Available for sale securities, net loss reclassified into income, Net	20,700	0	162,865	0
Net change in unrealized gains (losses) on available for sale securities, Net	(3)	9,750	56,510	(8,365)
Other comprehensive (loss) income, Net			56,510	(8,365)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(692)	686	341	900
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	270	(270)	(129)	(355)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	(422)	416	212	545
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	16	971	2,323	1,172
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(708)	(285)	(1,982)	(272)
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(692)	686	341	900
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Tax Effect	(6)	(382)	(902)	(462)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	276	112	773	107
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	270	(270)	(129)	(355)
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Net	10	589	1,421	710
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(432)	(173)	(1,209)	(165)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	$ (422)	$ 416	212	545
Other comprehensive (loss) income, Net			$ 212	$ 545

Business Segments - Additional

Business Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017Segment
Segment Reporting Information [Line Items]
Number of reportable segments	3
Number of operating segments	8
Population Health [Member]
Segment Reporting Information [Line Items]
Number of operating segments	4

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 449,442	$ 392,384	$ 1,289,008	$ 1,124,463
Gross Profit	201,919	166,159	568,062	484,741
Income from operations	25,373	16,874	57,740	47,344
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	1,986	1,538	4,197	26,606
Gross Profit	(9,896)	(11,233)	(32,190)	(21,755)
Income from operations	(79,915)	(69,598)	(239,298)	(213,871)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	303,323	276,503	870,452	830,200
Gross Profit	130,224	113,677	363,228	349,017
Income from operations	68,837	59,921	186,846	188,145
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	60,515	61,722	179,313	170,803
Gross Profit	41,947	46,337	125,535	125,152
Income from operations	29,298	32,977	86,282	81,895
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	83,618	52,621	235,046	96,854
Gross Profit	39,644	17,378	111,489	32,327
Income from operations	$ 7,153	$ (6,426)	$ 23,910	$ (8,825)

Supplemental Disclosures - Addi

Supplemental Disclosures - Additional Information (Detail)	Sep. 30, 2017LetterOfCredit
Netsmart [Member]
Schedule Of Supplemental Disclosures [Line Items]
Number of letter of credit maintained	2

Summary of Reconciliation of Ca

Summary of Reconciliation of Cash and Cash Equivalent, Restricted Cash and Supplemental Non-Cash Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 104,301	$ 76,636	$ 104,301	$ 76,636	$ 95,607
Restricted cash	5,123	615	5,123	615	1,003
Total cash, cash equivalents and restricted cash	109,424	77,251	109,424	77,251	$ 96,610	$ 116,873
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	$ 10,962	$ 10,191	32,887	18,344
Obligations incurred to purchase capitalized software or enter into capital leases			11,515	0
Issuance of treasury stock to commercial partner			334	0
NantHealth, Inc. [Member]
Supplemental non-cash information:
Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management			42,750	0
Netsmart Inc Management
Supplemental non-cash information:
Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock - Netsmart by Netsmart, Inc. management			$ 0	$ 25,543

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - McKesson Corporation [Member] $ in Millions	Oct. 02, 2017USD ($)Subsidiary
Subsequent Event [Line Items]
Number of wholly owned subsidiaries in which outstanding equity interest acquired | Subsidiary	2
Purchase price net of adjustments | $	$ 185